Organogenesis Holding (ORGO) Prices 17.5M Share Common Stock Offering at $3.25/sh

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the pricing of an underwritten public offering of 17,500,000 shares of its Class A common stock, offered at a price to the public of $3.25 per share. The gross proceeds to Organogenesis Holdings from this offering are expected to be approximately $56.9 million, before deducting the underwriting discounts and commissions and other offering expenses payable by Organogenesis Holdings. Organogenesis Holdings has granted the underwriters a 30-day option to purchase up to an aggregate of 2,625,000 additional shares of its Class A common stock. The offering is expected to close on or about November 17, 2020, subject to customary closing conditions.

Morgan Stanley & Co. LLC and SVB Leerink LLC are acting as joint book-running managers of the offering and BTIG, LLC and Oppenheimer & Co. Inc. are acting as co-managers for the offering.

Organogenesis Holdings intends to use the net proceeds from this offering, together with other available funds, for working capital and general corporate purposes, including, but not limited to, facility expansion and manufacturing enhancements, salesforce expansion and to conduct clinical studies of, obtain regulatory approvals and additional commercial insurance coverage for its products. The Company will retain broad discretion to allocate the proceeds.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• Nautilus Biotechnology (NAUT) files $300M mixed shelf
• Gaxos.ai (GXAI) files for 6.17M share offering by selling stockholders